Liraglutide + PYY_3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements.

ABSTRACT:

Background

Treatment options for NAFLD are still limited. Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB), has been shown to improve metabolic and histologic markers of NAFLD. Glucagon-like-peptide-1 (GLP-1) analogues lead to improvements in phase 2 clinical trials. We directly compared the effects of RYGB with a treatment using liraglutide and/or peptide tyrosine tyrosine 3-36 (PYY_3-36) in a rat model for early NAFLD.

Methods

Obese male Wistar rats (high-fat diet (HFD)-induced) were randomized into the following treatment groups: RYGB, sham-operation (sham), liraglutide (0.4 mg/kg/day), PYY_3-36 (0.1 mg/kg/day), liraglutide+PYY_3-36, and saline. After an observation period of 4 weeks, liver samples were histologically evaluated, ELI

SUBMITTER: Metzner V 

PROVIDER: S-EPMC8836549 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature